|Bid||1.9400 x 3000|
|Ask||1.9600 x 4000|
|Day's Range||1.7200 - 1.9900|
|52 Week Range||0.4100 - 7.1000|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 06, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
Upon commencement of the effective periods of these agreements, the Company will be the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States, and will also have distribution rights for the MYOLYN MyoCycle Functional Electrical Stimulation (“FES”) cycles to U.S. rehabilitation clinics and personal sales through the U.S. Department of Veterans Affairs (“VA”) hospitals. The MYOLYN MyoCycles use FES to facilitate therapeutic exercise for persons with muscle weakness or paralysis caused by disorders like spinal cord injury, multiple sclerosis, and stroke.
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced that the Centers for Medicare and Medicaid Services ("CMS") conducted a public hearing to discuss requests for new billing codes including CMS's positive preliminary decision for ReWalk's request for a Healthcare Common Procedure Coding System (HCPCS) Level II Code. The preliminary decision is an important moment for exoskeleton devices, which to date, have not had a distinct HCPCS billing code for claim submissions.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
ReWalk (RWLK) delivered earnings and revenue surprises of -42.31% and -65.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of ReWalk Robotics (NASDAQ:RWLK) moved higher by 2.4% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 70.40% over the past year to ($0.37), which missed the estimate of ($0.26).Revenue of $760,000 decreased by 51.93% year over year, which missed the estimate of $2,200,000.Outlook ReWalk Robotics hasn't issued any earnings guidance for the time being.ReWalk Robotics hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 28, 2020View more earnings on RWLKTime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/fm2cohrhRecent Stock Performance Company's 52-week high was at $10.08Company's 52-week low was at $0.41Price action over last quarter: Up 61.80%Company Description ReWalk Robotics Ltd is an Israel based medical device company. It is engaged in designing, developing and commercializing the Rewalk systems which are exoskeletons allowing wheelchair-bound individuals to stand and walk once again. The ReWalk systems allow the users to sit, stand, walk, turn and have the ability to climb and descend stairs. It offers two systems, ReWalk Personal which is designed for every day and all day use by individuals at home and in their communities and is custom-fit for each user; and ReWalk Rehabilitation which is designed for the clinical rehabilitation environment where it provides the user with valuable training exercise and therapy. The company generates maximum revenue from the United States and Europe.See more from Benzinga * 14 Technology Stocks Moving In Thursday's Pre-Market Session * 14 Industrials Stocks Moving In Thursday's Pre-Market Session * 9 Financial Services Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
— Q1 2020 Total Revenue of $0.8 million at a reduced level due to COVID-19 pandemic — — German coverage broadly expanded with social accident and statutory insurance —.
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 26, 2020 -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will.
Four years after entering into a collaboration with researchers at Harvard University to develop wearable exosuits for patients with limited mobility, ReWalk Robotics Ltd. (Nasdaq: RWLK)("ReWalk," "we" or the "Company") today announced a revision to the sponsored research agreement with Harvard to extend the term of the collaboration. Continuing the ongoing project until March 2023, the research team will investigate how their novel designs for wearable exosuits may incorporate features that support the increasing demand for tele-healthcare, including remote data provision, analysis and remote physical therapy for patients with their therapists.
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical devices for individuals with lower limb disabilities, announced the acceptance of the binding offer by DGUV (Deutsche Gesetzliche Unfallversicherung / The German Social Accident Insurance) to provide qualified spinal cord injury (SCI) patients with the ReWalk 6.0 robotic exoskeleton device. This binding offer applies for the provision of ReWalk Exoskeletons for all insured persons of the 36 different DGUV members/insurances. In 2018, nearly 83 million Germans were insured against work-related, commuting and school accidents and against occupational diseases under DGUV.
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical devices for individuals with lower limb disabilities, has announced the finalization of national agreements with top German Statutory Health Insurers ("SHI") Techniker Krankenkasse ("TK") and Deutsche Angestellten-Krankenkasse – Gesundheit ("DAK-Gesundheit"). These new policies will allow any eligible beneficiary with a spinal cord injury ("SCI") to seek procurement of a ReWalk 6.0 exoskeleton system. TK and DAK, representing 10.6 million and 5.6 million beneficiaries in Germany, respectively, are two of the largest SHIs in the country; these agreements are expected to help set the standard for exoskeleton procurement in Germany.
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, March 24, 2020 -- ReWalk Robotics Ltd. (Nasdaq: RWLK) a global leader in Exoskeleton technology for community use and.
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical devices for individuals with lower limb disabilities has announced the finalization of an agreement with a group of German statutory health insurer (SHI) to allow any eligible beneficiary with a spinal cord injury (SCI) in the country to seek procurement of a ReWalk 6.0 exoskeleton system.
ReWalk Robotics Ltd. (NASDAQ:RWLK) shares fell 2.1% to US$0.82 in the week since its latest full-year results. It...
— 2019 Total Revenue of $4.9 million and $1.2 million During the Fourth Quarter of 2019 — — Completed and Pending German Insurance Contracts Establish the Implementation.
NEW YORK, NY / ACCESSWIRE / February 20, 2020 / ReWalk Robotics Ltd. (NASDAQ:RWLK) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 20, 2020 at ...
MARLBOROUGH, Mass., BERLIN and YOKNEAM ILIT, Israel, Feb. 17, 2020 -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will.
Each unit sold in this offering contains one ordinary share and one common warrant to purchase one ordinary share. Each pre-funded unit sold in this offering contains one pre-funded warrant to purchase one ordinary share at an exercise price of $0.001 per share and one common warrant to purchase one ordinary share. ReWalk intends to use the net proceeds from the offering for (i) sales, marketing and reimbursement expenses related to market development activities of the ReStore™ device and broadening third-party payor coverage for the ReWalk Personal device, (ii) research and development costs related to developing the Company’s lightweight exo-suit technology for various lower limb disabilities, including stroke and other indications affecting the ability to walk as well as continued development of its spinal cord injury device, and (iii) general corporate purposes.
ReWalk (RWLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Each unit contains one ordinary share (or ordinary share equivalent) and one common warrant to purchase one ordinary share. The ordinary shares (or ordinary share equivalents) and common warrants included in the units can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about February 10, 2020, subject to customary closing conditions.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo